Epilepsy Clinical Trial
Official title:
EEG-fMRI: Towards a Useful Clinical Tool in Epilepsy
The purpose of this project is to develop the method of combined recording of electroencephalography (EEG) and functional magnetic resonance imaging (fMRI) in order to improve understanding of the relationship between electrical (EEG) and blood flow (fMRI) responses to epileptic discharges as a necessary step towards clinical use. One factor that currently limits the use of EEG−fMRI in patients with epilepsy is that a relatively large proportion of patients do not show any fMRI response despite epileptic activity having been detected on the EEG recorded during scanning. The reasons for this are unclear, which makes it difficult to predict in advance whether useful information will be gained from the scanning session. What is it about some epileptic discharges that results in a detectable change in the fMRI signal, while others which are no less obvious or frequent do not? This question will be addressed by determining the factors that are responsible for the occurrence of robust fMRI signal changes via detailed morphological, topographical and spectral analysis of the EEG signal on an event by event basis.
The purpose of the project is to continue the development of a new method of localising the
regions of the brain responsible for abnormal, epileptic discharges in patients with
epilepsy. The method, EEG−fMRI, combines electroencephalography (EEG) and functional
magnetic resonance imaging (fMRI). EEG records the electrical activity of the brain via
electrodes attached to the scalp, and is widely used in the diagnosis and study of epilepsy.
FMRI uses an MRI scanner to detect changes in blood flow that occur whenever a region of the
brain is active. Both techniques have a wide range of applications in the study of normal
and abnormal brain function.
The advantage of combining the two techniques is that fMRI can determine very accurately the
location of the active regions, while EEG has the potential to unlock their relative timing,
allowing more accurate interpretation of fMRI results and hence the brain response to
epileptic activity. The project will not be applied to the localisation of epileptic
seizures, because of their unpredictability, the safety implications of having a seizure in
an MRI scanner and problems with data quality if the patient moves during scanning. Instead,
interictal discharges will be studied, which are small events occurring regularly between
seizures of which the patient is unaware.
Clinically, it can be extremely important to determine which regions of the brain generate
epileptic discharges, both for a better understanding of the patient's epilepsy and, in
suitable cases, to help in planning surgery. EEG−fMRI is one method of doing this, and is
potentially very powerful because it is very straightforward for the patient, requiring only
the application of electrodes to the scalp followed by a period lying down in the MRI
scanner. In addition, since most UK hospitals have MRI scanners and EEG expertise, it could
take advantage of capacity that already exists within the NHS. This project will build on
previous work to characterise the link between the electrical (EEG) and blood flow (fMRI)
responses to interictal discharges which is necessary in order for the technique to become
widely used clinically.
Patients will be recruited from epilepsy clinics after having the nature and purpose of the
project explained to them. They will also receive initial screening for MRI safety to ensure
that they can be scanned safely. Upon arrival at the Birmingham University Imaging Centre
(BUIC), EEG electrodes will be attached to the patient's scalp using an electrode cap. When
the electrodes are in place, the patient will be asked to lie down on the scanner bed. Ear
plugs and head phones will be worn to minimise the noise of the scanner but this will not
prevent communication with the scanner operator. Once the bed has been moved to the centre
of the scanner, the patient will be asked to lie still for the remainder of the scanning
session. No task will be performed. Scanning will include an anatomical image and multiple
runs of fMRI. The patient will have an alarm bell which can be pressed at any time to
attract the attention of the scanner operator, and fMRI scanning will have regular breaks
every 5−6 minutes during which the scanner operator will talk to the patient. During the
course of scanning the patient will be monitored from the control room via the window and
video camera. Scanning will continue for a maximum of two hours or until the patient
expresses the desire to terminate the session. The patient will then be removed from the
scanner and the electrodes removed, following which the patient will be free to leave BUIC.
It is expected that the whole procedure will take up to 3 hours and will be conducted once
per patient, although if a patient expresses a willingness to return this may be considered.
Patients with a variety of types of epilepsy will be scanned. This will result in a
comprehensive database, taking into account losses due to poor quality data, patients who
wish to leave the scanner early and those in whom no interictal discharges are observed. The
main result of the study will be to compare the properties of the fMRI response to the
corresponding properties of each interictal discharge, in order to determine why some
discharges are detectable by fMRI, while others are not. This will be done on a patient by
patient basis, although comparison across patients with similar types of epilepsy will begin
to help determine which patients are suitable for EEG−fMRI, a crucial question if the
technique is to be applied efficiently and effectively.
;
Observational Model: Case-Only
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04595513 -
Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants
|
Phase 1/Phase 2 | |
Completed |
NCT02909387 -
Adapting Project UPLIFT for Blacks in Georgia
|
N/A | |
Completed |
NCT05552924 -
Self Acupressure on Fatigue and Sleep Quality in Epilepsy Patients
|
N/A | |
Terminated |
NCT01668654 -
Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS
|
Phase 3 | |
Not yet recruiting |
NCT05068323 -
Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients
|
N/A | |
Completed |
NCT03994718 -
Creative Arts II Study
|
N/A | |
Recruiting |
NCT04076449 -
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
|
||
Completed |
NCT00782249 -
Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy
|
N/A | |
Completed |
NCT03683381 -
App-based Intervention for Treating Insomnia Among Patients With Epilepsy
|
N/A | |
Recruiting |
NCT05101161 -
Neurofeedback Using Implanted Deep Brain Stimulation Electrodes
|
N/A | |
Active, not recruiting |
NCT06034353 -
Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients
|
N/A | |
Recruiting |
NCT05769933 -
Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
|
||
Not yet recruiting |
NCT06408428 -
Glioma Intraoperative MicroElectroCorticoGraphy
|
N/A | |
Not yet recruiting |
NCT05559060 -
Comorbidities of Epilepsy(Cognitive and Psychiatric Dysfunction)
|
||
Completed |
NCT02977208 -
Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use
|
Phase 4 | |
Completed |
NCT02646631 -
Behavioral and Educational Tools to Improve Epilepsy Care
|
N/A | |
Completed |
NCT02952456 -
Phenomenological Approach of Epilepsy in Patients With Epilepsy
|
||
Recruiting |
NCT02539134 -
TAK-935 Multiple Rising Dose Study in Healthy Participants
|
Phase 1 | |
Terminated |
NCT02757547 -
Transcranial Magnetic Stimulation for Epilepsy
|
N/A | |
Completed |
NCT02491073 -
Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)
|
N/A |